免疫抑制剂布雷迪宁预防异种肾移植术后急性排斥反应的临床效果评价

Evaluation of immunosuppressant mizoribine in preventing acute renal xenogeneic rejection

目的:探讨布雷迪宁联合环孢素A、强的松预防异种肾移植术后急性排斥反应的有效性与安全性.方法:首次接受肾移植患者60例随机分为治疗组(n=30)和对照组(n=30),对照组采用霉酚酸酯+环孢素A+强的松常规3联免疫抑制方案治疗,治疗组采用布雷迪宁+环孢素A+强的松方案治疗,观察术后6mo内急性排斥反应(AR)的发生率和发生时间、血肌酐平均下降速度、骨髓抑制和胃肠道反应发生率等.结果:治疗组AR发生率和发生时间低于对照组(P<0.05),且术后血肌酐平均下降速度高于对照组(P<0.05);两种治疗方案骨髓抑制发生率无显著性差异,但治疗组胃肠道反应发生率显著低于对照组(P<0.05).结论:布雷迪宁预防异种肾移植术后急性排斥反应临床效果好,毒副作用低.

AIM：To investigate the efficacy and safety of mizoribine combined with cyclosporine （CsA） and prednisone in preventing acute renal xenogeneic rejection. METHODS：Sixty patients with kidney transplantation were randomly divided into treatment group （30 cases） and control group （30 cases）. The patients in treatment group were treated with mizoribine plus CsA and prednisone,while the patients in control group were treated with mycophenolate mofetil plus CsA and prednisone as usual. The acute rejection rate and time,the reduction rate of serum creatinine,the incidence of bone marrow suppression and the gastrointestinal tract reaction were observed and analyzed 6 months post-transplantation. RESULTS：The rejection rate and time in the treatment group was significantly lower but the average reduction rate of serum creatinine was significantly higher compared with those in the control group （both,P〈0.05）. No significant difference was observed in the incidence of bone marrow suppression between the two groups （P〉0.05）,but the incidence of gastrointestinal reaction in the treatment group was significantly lower than that in the control group （P〈0.05）. CONCLUSION：Mizoribine with low toxicity effectively prevents acute renal xenogeneic rejection.